Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress [Yahoo! Finance]
Tourmaline Bio, Inc. (TRML)
Company Research
Source: Yahoo! Finance
These posters highlight Tourmaline's ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition. Poster Presentations Title Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention Authors : Emil deGoma, MD ; Yung Chyung, MD ; John Walsh, MD ; C. William Pike, MD ; Jananee Muralidharan, MD ; Vincent Marino ; J. Craig Davis ; Saurabh Gombar, MD, PhD ; Michael D. Shapiro, DO, MCR Affiliations Tourmaline Bio, Inc., New York, NY, USA Atropos Health, Inc., New York, NY, USA Wake Forest University School of Medicine, Winston-Salem, NC, USA Title Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis Authors Saeid Mirzai, DO ; Emil deGoma, MD ; John Walsh, MD ; Raya Mahbuba, MSc ; Yung Chyung, MD ; Michael D. Shapiro, DO, MCR Affiliations Wake Forest University School of Medicine, Winston-Salem, NC, USA Tour
Show less
Read more
Impact Snapshot
Event Time:
TRML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRML alerts
High impacting Tourmaline Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TRML
News
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.MarketBeat
- Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day [Yahoo! Finance]Yahoo! Finance
- Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor DayGlobeNewswire
TRML
Earnings
- 11/7/24 - Beat
TRML
Sec Filings
- 12/10/24 - Form 8-K
- 12/10/24 - Form 8-K
- 11/15/24 - Form EFFECT
- TRML's page on the SEC website